New York’s decision to decouple from federal R&E tax treatment creates a meaningful shift for manufacturing and distribution companies that depend on continuous innovation. By requiring multi-year amortization of these costs at the state and city level, businesses may face higher near-term taxable income and added cash flow pressure, particularly when investing in automation, process improvements, and technology. The change also introduces greater complexity, requiring separate tracking and planning across jurisdictions.
Overview of New York’s R&E Tax Decoupling and Its Impact
Included in New York’s recently enacted Fiscal Year 2027 State Budget, passed on May 27, 2026 (awaiting the Governor’s signature), lawmakers approved a significant tax change that directly affects how manufacturing and distribution businesses treat certain research and development (R&D) costs for New York State and New York City (NYS/NYC) tax purposes. The change is retroactive, effective for tax years beginning on or after January 1, 2025, and impacts 2025 returns currently being prepared.
The change stems from Parts F and G of the tax budget bill (the “Budget Bill”), which decouples NYS and NYC tax law from specific federal benefits enacted under the One Big Beautiful Bill Act (OBBBA). Most notably, the Budget Bill decouples from the federal restoration of immediate expensing for R&E expenditures under Internal Revenue Code Section 174A, as well as certain accelerated depreciation and expensing provisions, changing how these costs are treated for NYS and NYC tax purposes
While federal rules still apply for federal filings, New York’s decision not to conform means manufacturers and distributors must now apply a different, and less favorable, treatment at the state and city level. As a result, New York has effectively increased the cost of innovation and investment for businesses operating in the state.
What Does “Decoupling” Mean?
New York generally conforms to the federal tax code on a rolling basis, automatically adopting federal changes as they take effect. Decoupling means the state has chosen not to follow specific federal provisions. While New York has historically conformed to federal treatment of research and experimental (R&E) expenditures under Internal Revenue Code Section 174 since 2001, this legislation represents a notable shift away from that long-standing conformity.
Under the enacted budget provisions:
- NYS and NYC will not conform to the federal treatment, allowing immediate expensing of R&E costs.
- Instead, R&E costs must be amortized over five years for state and city tax purposes.
- New York City applies a mid‑year convention, creating timing differences between federal, state, and city returns.
- Comparable decoupling applies to certain accelerated depreciation and expensing provisions.
- Interest and penalty relief is provided for underpayments attributable to the retroactive decoupling.
Why This Matters to Manufacturing and Distribution Businesses
Many companies in the manufacturing and distribution sector do not view their operations as “research and development.” However, under the tax code, R&E encompasses a broad range of operational activities that involve experimentation to improve products or processes.
In practice, qualifying activities often include:
- Designing or improving products, components, or materials
- Developing and testing automated production lines, robotics, or machining processes
- Creating or enhancing proprietary software, such as warehouse management or logistics systems
- Improving production efficiency, waste reduction, or sustainability
- Testing formulations, shelf life, or production consistency
Because these activities are core to maintaining competitiveness, many companies have historically benefited from immediate federal expensing of R&E costs. New York’s decoupling now accelerates state and city taxable income, even when federal tax liability remains unchanged.
Key Impacts to Watch
For manufacturers and distributors operating in New York, this change may result in:
- Higher NYS and NYC taxable income compared to federal returns
- Timing differences requiring separate federal, state, and city calculations
- Cash flow considerations, particularly for companies investing heavily in automation or product development
- Increased compliance complexity, including additional tracking and amortization schedules
- Immediate retroactive impact on 2025 filings and estimated payments
Planning Ahead
This change underscores the importance of proactive tax planning. Now is an appropriate time to:
- Re‑evaluate how R&E activities are identified and documented.
- Build and maintain separate NYS and NYC amortization schedules for R&E costs.
- Model the state and city tax impact on cash flow and estimated payments.
- Align capital investment and innovation planning with longer recovery periods.
- Review the impact on accrued NYS and NYC pass-through entity tax deductions to optimize the federal taxable income benefit.
Connect with your Grassi advisor to discuss how New York’s decoupling may affect your manufacturing or distribution business and upcoming investment decisions.
